ML 2-14

• Description :

  ML 2-14 is a PROTAC targeting BRD4 with a C4 alkyl linker. ML 2-14 consists of the E3 ligase ligand EN219 (HY-115715) (bule part), the target protein ligand JQ-1 (HY-13030) (red part), and the PROTAC linker (balck part) . ML 2-14 can effectively degrade BRD4 in 231MFP breast cancer cells, and this effect can be reversed by the proteasome inhibitor Bortezomib (HY-10227) and the E1 activase inhibitor TAK-243 (HY-100487) [1].

• UNSPSC :

  12352005

• Target :

  Epigenetic Reader Domain; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; PROTAC

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ml-2-14.html

• Purity :

  99.43

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  ClC1=CC=C(C=C1)C2=N[C@@H](CC(NCCCCOC3=CC=C(C4CC(C5=CC=C(Br)C=C5)=NN4C(CCl)=O)C=C3)=O)C6=NN=C(C)N6C7=C2C(C)=C(C)S7

• Molecular Formula :

  C40H38BrCl2N7O3S

• Molecular Weight :

  847.65

• References & Citations :

  [1]Luo M, et al. Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function. Cell Chem Biol. 2021;28 (4) :559-566.e15.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  BRD4